Please login to the form below

Not currently logged in
Email:
Password:

CRS-207

This page shows the latest CRS-207 news and features for those working in and with pharma, biotech and healthcare.

Aduro pancreatic cancer vaccine trial disappoints

Aduro pancreatic cancer vaccine trial disappoints

The immunotherapy combines CRS-207 - a drug that promotes the expression of the tumour-associated antigen mesothelin - with an immune-boosting GVAX cell line, and is Aduro's lead product candidate. ... The regimen was unable to improve overall survival

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics